Atidarsagene Autotemcel

Brand names: Lenmeldy · Active ingredient: Atidarsagene Autotemcel

In short: LENMELDY is indicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD).

Forms & strengthsLENMELDY is a single-dose cell suspension for intravenous infusion. LENMELDY is composed of one to eight infusion bags which contain 2 to 11.8 × 10 6cells/mL (1.8 to 11.8 x 10 6CD34 +cells/mL) suspended in cryopreservation solution . …
LabelOrchard Therapeutics (Europe) Ltd
Label updatedOct 05, 2026

What is Atidarsagene Autotemcel used for?

LENMELDY is indicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD).

Atidarsagene Autotemcel dosage

For autologous use only. For one-time single-dose intravenous use only.

LENMELDY is provided as a single dose for infusion containing a suspension of CD34

+cells in one to eight infusion bags. Table 1 provides the minimum and maximum recommended dose of LENMELDY based on MLD disease subtype:

MLD Subtype | Minimum Recommended Dose

(CD34

+cells/kg) | Maximum Recommended Dose

(CD34

+cells/kg)

Pre-symptomatic late infantile | 4.2 x 10

6 | 30 x 10

6

Pre-symptomatic early juvenile | 9 x 10

6 | 30 x 10

6

Early symptomatic early juvenile | 6.6 x 10

6 | 30 x 10

6

The dose administered is calculated based on the child’s weight at time of LENMELDY infusion using the information provided on the Lot Information Sheet. See the Lot Information Sheet provided with the product shipment for additional information pertaining to dose.

Mobilization, apheresis, and myeloablative conditioning are required prior to LENMELDY infusion. Before initiating these procedures, confirm that hematopoietic stem cell (HSC) gene therapy is appropriate for the child.

Screen children for hepatitis B virus (HBV), hepatitis C virus (HCV), human T-lymphotrophic virus 1 & 2 (HTLV-1/HTLV-2), human immunodeficiency virus 1 & 2 (HIV-1/HIV-2), cytomegalovirus (CMV), and mycoplasma infection in accordance with clinical guidelines before collection of cells for manufacturing.

Mobilization and Apheresis

Children are required to undergo HSC mobilization followed by apheresis to obtain CD34

+cells for LENMELDY manufacturing. In clinical trials of LENMELDY, granulocyte-colony stimulating factor (G-CSF) with or without plerixafor was used for mobilization.

For the manufacture of LENMELDY, a collection of a minimum of 8.0 × 10

6CD34

+cells/kg of autologous cells is required based on a weight at time of apheresis collection. Collection of the minimum number of CD34

+cells required for manufacture may be achieved using one or more cycles of mobilization.

A collection of unmanipulated back-up CD34

+cells of at least 2.0 × 10

6CD34

+cells/kg is required. These cells must be collected from the child and be cryopreserved prior to myeloablative conditioning. The back-up collection may be needed for rescue treatment if there is: 1) compromise of LENMELDY after initiation of conditioning but before infusion, 2) primary engraftment failure, or 3) loss of engraftment after infusion with LENMELDY. The back-up cells may be collected either through mobilized peripheral blood (mPB) apheresis or bone marrow collection.

Myeloablative Conditioning

Myeloablative conditioning must be administered before infusion of LENMELDY. In clinical trials of LENMELDY, busulfan was used for myeloablative conditioning. There is no data available supporting the use of alternative conditioning agents with LENMELDY. …

How to take Atidarsagene Autotemcel — instructions & advice from the label

Ensure that patients and/or caregivers understand the risk of manufacturing failure. A collection of unmanipulated back-up CD34

+cells is required in case of manufacturing failure. These cells must be collected from the patient and be cryopreserved prior to myeloablative conditioning .

Prior to treatment, advise patients and/or caregivers of the following:

Risks associated with mobilization and myeloablative conditioning agents [

see

Preparation before LENMELDY Infusion (2.2),

Use in Specific Populations(

8.1,

8.3)

].

Risk of Hypersensitivity Reactions - Although no cases have been reported to date, allergic reactions may occur with the infusion of LENMELDY. The dimethyl sulfoxide (DMSO) in LENMELDY may cause hypersensitivity reactions, including anaphylaxis .

After treatment, advise patients and/or caregivers of the following:

Thrombosis and Thrombotic Event-A risk of blood clots may occur. Monitor patients for signs and symptoms of thrombosis .

Encephalitis- Monitor patients for signs or symptoms of encephalitis, including neurological deterioration such as weakness, decreased muscle tone, cognitive deterioration, behavioral problems, vomiting, and swallowing difficulties . …

Warnings & precautions

Do not take this medicine if: None.

Treatment with LENMELDY may increase the risk of thrombosis and thromboembolic events. A child with PSEJ MLD died after experiencing a left hemisphere cerebral infarction secondary to a thrombotic event in a large blood vessel approximately one year after treatment with LENMELDY. Prior to the cerebral infarction, the child’s D-dimer was elevated (82 nmol/L, normal range: 1.5 - 4.2). Additional clinical findings included a minor elevation of liver enzymes. The etiology of the cerebral infarction was unclear but attribution to LENMELDY cannot be ruled out. No other events related to cerebral infarction have been reported during the clinical development of LENMELDY.

Some children received anti-thrombotic prophylaxis . Evaluate the risk factors for thrombosis prior to and after LENMELDY infusion according to best clinical practice.

Treatment with LENMELDY may increase the risk of encephalitis. A child with ESEJ MLD developed a serious event of encephalitis after treatment with LENMELDY. At the time of treatment, GMFC-MLD was Level 1 (able to walk independently with impaired gait). One month after treatment, the child experienced subacute neurological deterioration, with asthenia, hypotonia, cognitive and behavioral problems, vomiting, and swallowing disturbance. The child was afebrile, blood and CSF cultures were negative for bacterial infection, a large viral panel was negative and all routine laboratory tests were normal. The child was treated with plasmapheresis, immunoglobulin and rituximab leading to clinical improvement. Five months after onset of symptoms the child had reached GMFC-MLD Level 4 (walking not possible; able to sit without support and locomotion possible, or unable to sit without support but locomotion is possible). The child was subsequently treated with eculizumab and tocilizumab. …

Atidarsagene Autotemcel side effects

The most common non-laboratory adverse reactions (occurring in ≥10% of all children within Year 1 of treatment) were: febrile neutropenia (85%), stomatitis (77%), respiratory tract infections (54%), rash (33%), device related infections (31%), other viral infections (28%), pyrexia (21%), gastroenteritis (21%), and hepatomegaly (18%).

The following clinically significant adverse reactions are described elsewhere in the labeling:

Thrombosis and Thrombotic Events

Encephalitis

Serious Infection

Veno-occlusive Disease

Delayed Platelet Engraftment

Neutrophil Engraftment Failure

Insertional Oncogenesis

Hypersensitivity Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data reflect experience from 39 children with MLD treated in clinical trials of LENMELDY: PSLI (n=20), PSEJ (n=7), ESEJ (n=10), and 2 children with advanced disease at the time of treatment . The median (min, max) years of follow-up for the safety population was 6.8 (0.6, 12.2).

Table 2 presents the non-laboratory treatment emergent adverse reactions occurring in ≥10% of all children with onset reported on or after the date of conditioning up to 1 year follow-up post-treatment. …

Drug interactions

No formal drug interaction studies have been performed. LENMELDY is not expected to interact with the hepatic cytochrome P-450 family of enzymes or drug transporters.

The safety and effectiveness of vaccination during or following LENMELDY treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding the start of myeloablative conditioning, and until hematological recovery following treatment with LENMELDY. Where feasible, administer childhood vaccinations prior to myeloablative conditioning for LENMELDY.

Children should not take anti-retroviral medications for at least one month prior to mobilization or the expected duration for elimination of the medications . Anti-retroviral medications may interfere with the manufacturing of LENMELDY.

About this medicine

LENMELDY (atidarsagene autotemcel) is a gene therapy consisting of autologous CD34

+cells, containing hematopoietic stem cells (HSCs), transduced with a lentiviral vector (LVV) encoding the human arylsulfatase A (ARSA) gene, suspended in cryopreservation solution. LENMELDY is intended for one-time administration to add functional copies of the ARSA gene into the child’s own HSCs.

LENMELDY is prepared from the child’s own HSCs, which are collected via apheresis procedure(s). The autologous cells are enriched for CD34

+cells, then transduced

ex vivowith a recombinant replication-incompetent self-inactivating (SIN) human immunodeficiency virus-1 (HIV-1) - based LVV that has been modified to carry the ARSA cDNA sequence under the human phosphoglycerate kinase (PGK) promoter. The transduced CD34

+cells are washed, formulated into a suspension, and then cryopreserved.

LENMELDY is manufactured for each individual child into infusion bags, which are cryopreserved before being thawed prior to administration . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b3e307a7-561b-43b6-a784-9cb1dcfc5196. Read the full official label on DailyMed.